Predicting the outcome of chemotherapy for colorectal cancer

Current Opinion in Pharmacology

Volumn 6, Issue 4, 2006, Pages 332-336

  Allen, Wendy L ^a   Coyle, Vicky M ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PLATINUM DERIVATIVE; PROTEIN P53;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DNA ADDUCT; DNA MICROARRAY; DNA REPAIR; DRUG ACCUMULATION; DRUG EXPOSURE; DRUG INACTIVATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; HUMAN; INDIVIDUALIZATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TIME; TREATMENT PLANNING; WESTERN HEMISPHERE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33745686060     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.02.005     Document Type: Review

References (50)

1. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., Chollet P., Llory J.F., Letourneau Y., Coudert B., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
2. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
3. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
4. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
5. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
6. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
7. Houghton J.A., Tillman D.M., and Harwood F.G. Ratio of 2′-deoxyadenosine-5′-triphosphate/thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res 1 (1995) 723-730
8. Johnston P.G., Drake J.C., Trepel J., and Allegra C.J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52 (1992) 4306-4312
9. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., and Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55 (1995) 1407-1412
10. Edler D., Blomgren H., Allegra C.J., Johnston P.G., Lagerstedt U., Magnusson I., and Ragnhammar P. Immunohistochemical determination of thymidylate synthase in colorectal cancer - methodological studies. Eur J Cancer 33 (1997) 2278-2281
11. Lenz H.J., Danenberg K.D., Leichman C.G., Florentine B., Johnston P.G., Groshen S., Zhou L., Xiong Y.P., Danenberg P.V., and Leichman L.P. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4 (1998) 1227-1234
12. Johnston PG, Benson AB III, Catalano PJ, Eapen S, Sargent DJ, McDermott U, Colangelo L, Wieand S, Wolmark N, Goldberg RM et al.: The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: an intergroup combined analysis. J Clin Oncol 2006. in press.
13. Metzger R., Danenberg K., Leichman C.G., Salonga D., Schwartz E.L., Wadler S., Lenz H.J., Groshen S., Leichman L., and Danenberg P.V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4 (1998) 2371-2376
14. Takebayashi Y., Miyadera K., Akiyama S., Hokita S., Yamada K., Akiba S., Yamada Y., Sumizawa T., and Aikou T. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 87 (1996) 288-295
15. Diasio R.B., and Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16 (1989) 215-237
16. Tsuji T., Sawai T., Takeshita H., Nakagoe T., Hidaka S., Yamaguchi H., Yasutake T., Nagayasu T., and Tagawa Y. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 54 (2004) 531-536
17. Takebe N., Zhao S.C., Ural A.U., Johnson M.R., Banerjee D., Diasio R.B., and Bertino J.R. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 8 (2001) 966-973
18. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
19. Etienne M.C., Chazal M., Laurent-Puig P., Magne N., Rosty C., Formento J.L., Francoual M., Formento P., Renee N., Chamorey E., et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20 (2002) 2832-2843
20. Ahnen D.J., Feigl P., Quan G., Fenoglio-Preiser C., Lovato L.C., Bunn Jr. P.A., Stemmerman G., Wells J.D., Macdonald J.S., and Meyskens Jr. F.L. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a southwest oncology group study. Cancer Res 58 (1998) 1149-1158
21. Liang J.T., Huang K.C., Cheng Y.M., Hsu H.C., Cheng A.L., Hsu C.H., Yeh K.H., Wang S.M., and Chang K.J. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97 (2002) 451-457
22. Elsaleh H., Powell B., McCaul K., Grieu F., Grant R., Joseph D., and Iacopetta B. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7 (2001) 1343-1349
23. Tang R., Wang J.Y., Fan C.W., Tsao K.C., Chen H.H., Wu C.M., Chen J.S., Changchien C.R., and Hsieh L.L. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 210 (2004) 101-109
24. Paradiso A., Simone G., Petroni S., Leone B., Vallejo C., Lacava J., Romero A., Machiavelli M., De Lena M., Allegra C.J., et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82 (2000) 560-567
25. Wang C., van Rijnsoever M., Grieu F., Bydder S., Elsaleh H., Joseph D., Harvey J., and Iacopetta B. Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology 64 (2003) 259-265
26. Adjei A.A. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48 (1999) 265-277
27. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., Groshen S., Tsao-Wei D.D., Danenberg P.V., and Lenz H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
28. Zhang K., Mack P., and Wong K.P. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 12 (1998) 871-882
29. Brabec V., and Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 5 (2002) 147-161
30. Rivory L.P., Bowles M.R., Robert J., and Pond S.M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52 (1996) 1103-1111
31. Hsiang Y.H., and Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48 (1988) 1722-1726
32. Humerickhouse R., Lohrbach K., Li L., Bosron W.F., and Dolan M.E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60 (2000) 1189-1192
33. Jansen W., Zwart B., Hulscher S., Giaccone G., Pinedo H., and Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterisation of cellular sensitivity determinants. Int J Cancer 70 (1997) 335-340
34. Vallbohmer D., and Lenz H.J. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 5 Suppl 1 (2005) S19-S27
35. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 (2001) 2958-2970
36. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., and Kerbel R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (1997) 1523-1530
37. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
38. Cascinu S., Staccioli M.P., Gasparini G., Giordani P., Catalano V., Ghiselli R., Rossi C., Baldelli A.M., Graziano F., Saba V., et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6 (2000) 2803-2807
39. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., Meropol N.J., Novotny W.F., Lieberman G., Griffing S., and Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
40. Giantonio B, Catalano P, Meropol N: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the eastern cooperative oncology group (ECOG) study E3200. GI cancers Symposium, 2005 Jan 27-29, Hollywood, FL. [Abstract number 169a].
41. Ince W.L., Jubb A.M., Holden S.N., Holmgren E.B., Tobin P., Sridhar M., Hurwitz H.I., Kabbinavar F., Novotny W.F., Hillan K.J., et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97 (2005) 981-989
42. Workman P., and Johnston P.G. Genomic profiling of cancer: what next?. J Clin Oncol 23 (2005) 7253-7256
43. Anderson L., and Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18 (1997) 533-537
44. Reid L.H., Crider-Miller S.J., West A., Lee M.H., Massague J., and Weissman B.E. Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms' tumor assay. Cancer Res 56 (1996) 1214-1218
45. Al-Mulla F., Keith W.N., Pickford I.R., Going J.J., and Birnie G.D. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 24 (1999) 306-314
46. Rooney P.H., Boonsong A., McKay J.A., Marsh S., Stevenson D.A., Murray G.I., Curran S., Haites N.E., Cassidy J., and McLeod H.L. Colorectal cancer genomics: evidence for multiple genotypes which influence survival. Br J Cancer 85 (2001) 1492-1498
47. Mariadason J.M., Arango D., Shi Q., Wilson A.J., Corner G.A., Nicholas C., Aranes M.J., Lesser M., Schwartz E.L., and Augenlicht L.H. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63 (2003) 8791-8812
48. Wang Y., Jatkoe T., Zhang Y., Mutch M.G., Talantov D., Jiang J., McLeod H.L., and Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22 (2004) 1564-1571. This was one of the first studies in CRC that attempted to generate a classifier marker set that was capable of predicting recurrence in Dukes' B and C CRC. The interesting component of this study is the two different methods used to generate the predictive model and the differing results that each generated, highlighting the need to build more than one model and test each of the predictive accuracies.
49. Eschrich S., Yang I., Bloom G., Kwong K.Y., Boulware D., Cantor A., Coppola D., Kruhoffer M., Aaltonen L., Orntoft T.F., et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23 (2005) 3526-3535. The extremely important component to this study is the use of an independent Danish validation set to test the predictive accuracy of their proposed model; this is crucial to any predictive analysis and is well demonstrated here.
50. Barrier A., Lemoine A., Boelle P.Y., Tse C., Brault D., Chiappini F., Breittschneider J., Lacaine F., Houry S., Huguier M., et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 24 (2005) 6155-6164. This study is of great importance as it goes one stage further than profiling tumours and attempts to generate a predictive model based on the non-neoplastic mucosa. The results show that, owing to the more homogenous nature of the non-neoplastic mucosa, the model appears to be more stable and is also able to predict recurrence with good accuracy.